• ESMO issues clinical guidelines for hereditary gastrointestinal cancers

    Emphasis is on prevention, diagnosis, treatment, and follow-up.

  • Pancreatic cancer: USPSTF doubles down on antiscreening position

    A reaffirmation of the 2004 recommendation against screening asymptomatic adults.

  • Pancreatic cancer: no benefit for intensified follow-up after curative resection

    US and European guidelines differ on recommendations.

  • PDAC: neoadjuvant chemotherapy ups resection, survival rates

    Real-world evidence supports clinical trial results.

  • In GI neuroendocrine neoplasms with liver metastasis, primary tumor resection linked to better survival

    Consider PTR in these patients, but factor age and primary tumor site, size, and differentiation into the decision.

  • Pancreatic cancer: neoadjuvant approach yields 61% complete resection rate

    Locally advanced pancreatic cancer has been historically considered to be unresectable.

  • New pancreatic NET sub-types help predict recurrence risk
    New pancreatic NET sub-types help predict recurrence risk

    Researchers found that non-functional pancreatic neuroendocrine tumours fall into two major sub-type categories.

  • Surgery yields excellent prognosis in pancreatic SPN

    Solid pseudopapillary neoplasms of the pancreas can often be resected completely.

  • Pancreatic NETs: no survival benefit for lymph node dissection

    Current guidelines recommend lymph node dissection, but evidence is lacking.

  • ASCO: adjuvant mFOLFIRINOX preferred for pancreatic cancer

    Update incorporates data from the PRODIGE 24/CCTG PA.6 trial.

  • Expert opinion: induction chemotherapy for locally advanced pancreatic cancer

    Surgeons, medical oncologists and gastrointestinal oncologists reviewed current evidence.

  • ESMO updates treatment guidelines for gastrointestinal cancers

    Reflects new data for liver, pancreatic, soft tissue, and gastric cancer.

  • Neoadjuvant trio improves outcomes in locally advanced pancreatic cancer

    A combination of aggressive chemotherapy, radiation, and a BP drug.

  • ASCO 2019 — Expert Commentary: Always test for BRCA in metastatic pancreatic cancer

    An interview with Hedy L. Kindler, MD, regarding the benefit of olaparib in BRCA-positive disease.

  • ASCO 2019 — Adjuvant nab-paclitaxel fails phase 3 trial for pancreatic cancer

    Addition to gemcitabine failed to improve DFS.

  • ASCO 2019 — Olaparib delays progression in BRCA+ pancreatic cancer

    Practice-changing findings from the phase 3 POLO trial.

  • Pancreatic cancer: survival unaffected by waiting time to surgery

    Nationwide population-based Danish cohort finds no effect of wait times.

  • Load more